Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sericin is a **silkworm-derived protein mixture** obtained from *Bombyx mori* cocoons and developed as a topical biologically active material rather than as a conventional single-molecule drug. Across the provided sources, sericin is described as having **anti-inflammatory and wound-healing activity**, including suppression of pro-inflammatory cytokines such as TNF-alpha, IL-6, IL-12p40, and IL-23 in ex vivo human peripheral blood mononuclear cells from patients with psoriasis, and promotion of corneal epithelial repair in ocular injury and diabetic keratopathy models. Clinical development in the provided records is mainly in **topical cream formulations** combined with chitosan for pressure sores and with turmeric for psoriasis, while publications also describe ophthalmic use as an additive to benzalkonium chloride-containing timolol eye drops. Sericin should be treated here as the specific active ingredient itself, not as the naringin + sericin combination product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sericin.